862 related articles for article (PubMed ID: 25442042)
41. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz RD
Br J Cancer; 2007 Mar; 96(6):912-7. PubMed ID: 17325705
[TBL] [Abstract][Full Text] [Related]
42. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Cercek A; Roxburgh CSD; Strombom P; Smith JJ; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Seier K; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Crane CH; Gollub MJ; Garcia-Aguilar J; Saltz LB; Weiser MR
JAMA Oncol; 2018 Jun; 4(6):e180071. PubMed ID: 29566109
[TBL] [Abstract][Full Text] [Related]
43. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
O'Connell MJ; Colangelo LH; Beart RW; Petrelli NJ; Allegra CJ; Sharif S; Pitot HC; Shields AF; Landry JC; Ryan DP; Parda DS; Mohiuddin M; Arora A; Evans LS; Bahary N; Soori GS; Eakle J; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Wozniak TF; Roh MS; Yothers G; Wolmark N
J Clin Oncol; 2014 Jun; 32(18):1927-34. PubMed ID: 24799484
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma.
Lay GC; Caraul B; Dessì M; Orrù S; Murtas R; Deidda MA; Farigu R; Farci D; Maxia L; Casula G; Amichetti M
J Exp Clin Cancer Res; 2007 Mar; 26(1):61-70. PubMed ID: 17550133
[TBL] [Abstract][Full Text] [Related]
45. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Velenik V; Ocvirk J; Oblak I; Anderluh F
Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
[TBL] [Abstract][Full Text] [Related]
46. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
47. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
Weiss C; Arnold D; Dellas K; Liersch T; Hipp M; Fietkau R; Sauer R; Hinke A; Rödel C
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):472-8. PubMed ID: 20133081
[TBL] [Abstract][Full Text] [Related]
48. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Nogué M; Salud A; Vicente P; Arriví A; Roca JM; Losa F; Ponce J; Safont MJ; Guasch I; Moreno I; Ruiz A; Pericay C;
Oncologist; 2011; 16(5):614-20. PubMed ID: 21467148
[TBL] [Abstract][Full Text] [Related]
49. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
[TBL] [Abstract][Full Text] [Related]
50. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
Park JH; Yoon SM; Yu CS; Kim JH; Kim TW; Kim JC
Cancer; 2011 Aug; 117(16):3703-12. PubMed ID: 21328328
[TBL] [Abstract][Full Text] [Related]
51. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
[TBL] [Abstract][Full Text] [Related]
52. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03.
Kim SY; Joo J; Kim TW; Hong YS; Kim JE; Hwang IG; Kim BG; Lee KW; Kim JW; Oh HS; Ahn JB; Zang DY; Kim DY; Oh JH; Baek JY
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):889-899. PubMed ID: 29976501
[TBL] [Abstract][Full Text] [Related]
53. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
54. Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy.
Lee SJ; Kang BW; Chae YS; Cho SH; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
Cancer Chemother Pharmacol; 2015 Jul; 76(1):29-34. PubMed ID: 25956708
[TBL] [Abstract][Full Text] [Related]
55. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
[TBL] [Abstract][Full Text] [Related]
56. Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial.
Xiao J; Chen Z; Li W; Yang Z; Huang Y; Zheng J; Deng Y; Wang L; Ren D; Peng J; Lan P; Wang J
Cancer Chemother Pharmacol; 2015 Jul; 76(1):21-7. PubMed ID: 25952796
[TBL] [Abstract][Full Text] [Related]
57. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Habr-Gama A; Perez RO; Sabbaga J; Nadalin W; São Julião GP; Gama-Rodrigues J
Dis Colon Rectum; 2009 Dec; 52(12):1927-34. PubMed ID: 19934911
[TBL] [Abstract][Full Text] [Related]
58. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
[TBL] [Abstract][Full Text] [Related]
59. Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
Movsas B; Hanlon AL; Lanciano R; Scher RM; Weiner LM; Sigurdson ER; Hoffman JP; Eisenberg BL; Cooper HS; Provins S; Coia LR
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):43-50. PubMed ID: 9747818
[TBL] [Abstract][Full Text] [Related]
60. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Glynne-Jones R; Mawdsley S; Harrison M
Acta Oncol; 2010 Apr; 49(3):278-86. PubMed ID: 20180626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]